Therapeutic challenges posed by critical drug–drug interactions in cystic fibrosis

Pediatric Pulmonology

Volumn 51, Issue , 2016, Pages S61-S70

  Jordan, Cameron L ^a   Noah, Terry L ^b   Henry, Marianna M ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cystic fibrosis (CF); pharmacology

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOXYCYCLINE; DULOXETINE; ERYTHROMYCIN; ESCITALOPRAM; ESOMEPRAZOLE; FLUCONAZOLE; FLUOXETINE; ITRACONAZOLE; IVACAFTOR PLUS LUMACAFTOR; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OMEPRAZOLE; PAROXETINE; POSACONAZOLE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; SERTRALINE; UNINDEXED DRUG; VORICONAZOLE;

CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; TREATMENT DURATION;

EID: 84988521421     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23505     Document Type: Review

References (62)

1. Goralski JL, Davis SD. Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: the current pipeline of therapeutics. Pediatr Pulmonol 2015; 40:S66–S73.
2. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009; 8:91–96.
3. Nichols DP, Kuk KN, Nick JA. Drug interactions and treatment burden as survival improves. Curr Opin Pulm Med 2015; 21:617–625.
4. Sawicki GS, Ren CL, Konstan MW, Millar SJ, Pasta DJ, Quittner AL. Investigators, coordinators of the epidemiologic study of cystic fibrosis. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros 2013; 12:461–467.
5. Mizokami F, Koide Y, Noro T, Furuta K. Polypharmacy with common diseases in hospitalized elderly patients. Am J Geriatr Pharmacother 2012; 10:123–128.
6. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother 2013; 47:324–332.
7. Pedros C, Formiga F, Corbella X, Arnau JM. Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. Eur J Clin Pharmacol 2016; 72:219–226.
8. Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr Med 2012; 28:159–172.
9. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging 2014; 9:2079–2086.
10. Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med 2012; 166:9–16.
11. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals. Pediatrics 2015; 135:e99–e108.
12. Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of polypharmacy and potential drug-drug interactions among pediatric patients in ICUs of U.S. children's hospitals. Pediatr Crit Care Med 2016; 17:e218–e228.
13. Ko Y, Malone DC, D'Agostino JV, Skrepnek GH, Armstrong EP, Brown M, Woosley RL. Potential determinants of prescribers' drug-drug interaction knowledge. Res Social Adm Pharm 2008; 4:355–366.
14. Ko Y, Malone DC, Skrepnek GH, Armstrong EP, Murphy JE, Abarca J, Rehfeld RA, Reel SJ, Woosley RL. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 2008; 31:525–536.
15. Zemanick ET, Ong T, Daines CL, Dellon EP, Muhlebach MS, Esther CR, Jr. Highlights from the 2015 North American Cystic Fibrosis Conference. Pediatr Pulmonol 2016; 51:650–657.
16. Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. J Am Acad Dermatol 2002; 47:467–484; quiz 485–468.
17. Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther 2014; 19:262–276.
18. Sikka R, Magauran B, Ulrich A, Shannon M. Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med 2005; 12:1227–1235.
19. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42:819–850.
20. Hay RJ, Clayton YM, Moore MK, Midgely G. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119:359–366.
21. New YorkNYVfend (voriconazole) [Prescribing information]. : Pfizer Inc.; 2006.
22. New YorkNYDiflucan (fluconazole) [Prescribing information]. : Pfizer Inc.; August 2004.
23. KenilworthNJNoxafil (posaconazole) [Prescribing information]. : Schering-Plough Corporation; October 2006.
24. Hafner R, Bethel J, Power M, Landry B, Banach M, Mole L, Standiford HC, Follansbee S, Kumar P, Raasch R, et al., Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42:631–639.
25. Garraffo A, Dellamonica P, Fournier JP, Lapalus P, Bernard E. The effect of rifampicin on the pharmacokinetics of doxycycline. Infection 1988; 16:297–298.
26. Hoover WC, Britton LJ, Gardner J, Jackson T, Gutierrez H. Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor. Ann Pharmacother 2011; 45:e38.
27. Gilchrist FJ, Cox KJ, Rowe R, Horsley A, Webb AK, Jones AM, Bright-Thomas RJ. Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression in adults with cystic fibrosis. J Cyst Fibros 2013; 12:399–402.
28. Albert BB, Jaksic M, Ramirez J, Bors J, Carter P, Cutfield WS, Hofman PL. An unusual cause of growth failure in cystic fibrosis: a salutary reminder of the interaction between glucocorticoids and cytochrome P450 inhibiting medication. J Cyst Fibros 2015; 14:e9–e11.
29. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525–538.
30. Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48:1441–1458.
31. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53:958–966.
32. Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, Nichols D. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56:56–61.
33. LouisMOCelexa (citalopram) [Prescribing information]. St. : Forest Laboratories, Inc.; August 2011.
34. Cipralex (escitalopram) [Product monograph]. Montreal (Quebec), Canada: Lundbeck Canada Inc.; March 2012.
35. LouisMOLexapro (escitalopram) [Prescribing information]. St. : Forest Laboratories, Inc.; December 2012.
36. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002; 35:197–200.
37. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881–1890.
38. Drug Administration. FDAFood and Drug Safety Communication: azithromycin and the risk of potentially fatal heart rhythms. http://www.fda.gov/drugs/drugsafety/ucm341822.htm.
39. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11:52–56.
40. Woosley RL, Romero KA. www.Crediblemeds.org QT drugs List [23 March 2016], AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755.
41. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A, Group TS. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial. Lancet 2005; 365:573–578.
42. Duff AJ. Depression in cystic fibrosis; implications of the International Depression/Anxiety Epidemiological Study (TIDES) in cystic fibrosis. Paediatr Respir Rev 2015; 16:2–5.
43. Pichini S, Papaseit E, Joya X, Vall O, Farre M, Garcia-Algar O, de laTorre R. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit 2009; 31:283–318.
44. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112–1120.
45. Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006; 26:1784–1793.
46. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578–1583.
47. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180–187.
48. Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. J Antimicrob Chemother 2012; 67:494–502.
49. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013; 57:3060–3066.
50. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014; 48:209–225.
51. Gaiser EC, Matuskey D, Perkins E, D'Amico C, Abdelghany O, McKee SA, Cosgrove KP. A case series on the heightened autonomic response due to guanfacine and amphetamine interaction. J Clin Psychopharmacol 2015; 35:197–199.
52. Erdogan A, Ozcay F, Piskin E, Karaman MG, Bilezikci B, Calik M, Tekin I, Haberal M. Idiosyncratic liver failure probably associated with atomoxetine: a case report. J Child Adolesc Psychopharmacol 2011; 21:295–297.
53. Aggarwal A, Kulkarni G, Jahan S. Potential serious adverse interactions between linezolid and atomoxetine. J Child Adolesc Psychopharmacol 2012; 22:405.
54. Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 2015; 11:1849–1859.
55. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol 2001; 41:563–572.
56. National Institutes of Health, U.S. National Library of Medicine, MedlinePlus https://www.nlm.nih.gov/medlineplus/druginfo/meds/a602004.html.
57. Kalydeco (ivacaftor) [Prescribing information]. Boston, MA: Vertex Pharmaceuticals, Inc.; March 2015.
58. Harrison MJ, Ronan NJ, Khan KA, O'Callaghan G, Murphy DM, Plant BJ. Ivacaftor therapy in siblings with cystic fibrosis-the potential implications of Itraconazole in dosage and efficacy. Pulm Pharmacol Ther 2015; 31:49–50.
59. Robertson SM, Luo X, Dubey N, Li C, Chavan AB, Gilmartin GS, Higgins M, Mahnke L. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol 2015; 55:56–62.
60. Orkambi (lumacaftor/ivacaftor) [Prescribing information]. Boston, MA: Vertex Pharmaceuticals, Inc.; July 2015.
61. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm. Accessed [3/24/ 2016].
62. Sawicki GS, Goss CH. Tackling the increasing complexity of CF care. Pediatr Pulmonol 2015; 50(Suppl 40):S74–S79.